Exelixis Inc Derivative Liability
Exelixis Inc (EXEL) had Derivative Liability of $921.00 thousand as of 2014-12-31, per its 10-K filed 2016-02-29.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2016-02-29
- 2014-12-31: Derivative Liability $921.00K.
- 2014-09-30: Derivative Liability $846.00K.
- 2014-06-30: Derivative Liability $908.00K.
- 2014-03-31: Derivative Liability $1.02M.
| Period end | Derivative Liability |
|---|---|
| 2014-12-31 | $921.00K 10-K · filed 2016-02-29 |
| 2014-09-30 | $846.00K 10-Q · filed 2014-11-04 |
| 2014-06-30 | $908.00K 10-Q · filed 2014-07-31 |
| 2014-03-31 | $1.02M 10-Q · filed 2014-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |